Table 5 Quality of evidence and summary of findings
Certainty assessment | Summary of findings | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Outcomes/ number of patients (number of studies) | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Overall certainty of evidence | Study event rates (%) | Relative effect (95% CI) | Anticipated absolute effects | ||
With Placebo | With Erenumab | Risk with Placebo | Risk difference with Erenumab | ||||||||
MMD at 3 months | |||||||||||
3606 (9 RCTs) | not serious | seriousa | not serious | not serious | publication bias suspectedb | ⨁⨁◯◯ Low | 1620 | 1986 | - | 1620 | MD 1.78 days per month lower (2.37 lower to 1.2 lower) |
MSMD at 3 months | |||||||||||
3007 (7 RCTs) | not serious | seriousa | not serious | not serious | publication bias suspectedb | ⨁⨁◯◯ Low | 1383 | 1624 | - | 1383 | MD 1.36 days per month lower (1.92 lower to 0.81 lower) |
HIT-6 at 3 months | |||||||||||
2725 (5 RCTs) | not serious | seriousa | not serious | not serious | publication bias suspectedb | ⨁⨁◯◯ Low | 1102 | 1623 | - | 1102 | MD 2.83 points lower (3.83 lower to 1.82 lower) |
≥ 50% reduction in MMD at 3 months | |||||||||||
3594 (8 RCTs) | not serious | seriousa | not serious | not serious | publication bias suspectedb | ⨁⨁◯◯ Low | 478/1600 (29.9%) | 884/1994 (44.3%) | RR 1.52 (1.31 to 1.76) | 478/1600 (29.9%) | 155 more per 1,000 (from 93 to 227 more) |